Vadimezan

Vadimezan
Clinical data
Other names	ASA404, DMXAA
ATC code	none;
Identifiers
	IUPAC name (5,6-Dimethyl-9-oxo-9H-xanthen-4-yl)-acetic acid;
CAS Number	117570-53-3 ;
ChemSpider	110486 ;
UNII	0829J8133H;
ChEBI	CHEBI:75934 ;
CompTox Dashboard (EPA)	DTXSID2040949 ;
ECHA InfoCard	100.107.097
Chemical and physical data
Formula	C17H14O4
Molar mass	282.295 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(OC(C(CC(O)=O)=CC=C3)=C3C2=O)C2=CC=C1C;
	InChI InChI=1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19) ; Key:XGOYIMQSIKSOBS-UHFFFAOYSA-N ;
	(what is this?) (verify)

Vadimezan (also known as or ASA404^[1] and dimethylxanthenone acetic acid or DMXAA) is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.^[2]

^ "New Zealand drug tested for breast-cancer fight". The New Zealand Herald. 14 February 2009. Retrieved 13 February 2009.
^ ASA404, A Novel Cancer Agent, Begins Pivotal Trial To Explore New Approach In Treating Lung Cancer, The Leading Cause Of Cancer Death, Medical News Today, 14 April 2008

[nzherald20090214-1] "New Zealand drug tested for breast-cancer fight". The New Zealand Herald. 14 February 2009. Retrieved 13 February 2009.

[2] ASA404, A Novel Cancer Agent, Begins Pivotal Trial To Explore New Approach In Treating Lung Cancer, The Leading Cause Of Cancer Death, Medical News Today, 14 April 2008

[1]

[2]